Owen Hughes
Directeur Général chez XOMA ROYALTY CORPORATION
Fortune : 133 635 $ au 30/06/2024
Profil
Owen Patrick Hughes is the founder of Triathlon Fund Management LLC (founded in 2003), Cullinan Therapeutics, Inc. (founded in 2016), and Cullinan Oncology LLC (founded in 2016).
He held the title of Partner at Triathlon Fund Management LLC.
He was the President, Chief Executive Officer & Director at Cullinan Therapeutics, Inc. and Cullinan Oncology LLC.
Mr. Hughes's current job(s) include being the Chief Executive Officer & Director at XOMA Corp.
since 2023, Chairman at Ikena Oncology, Inc. since 2022, Independent Director at C4 Therapeutics, Inc. since 2023, Director at Olivo Laboratories LLC, and Director at Wavebreak Therapeutics Ltd.
since 2018.
Mr. Hughes's former job(s) include being the Chief Executive Officer at Sail Bio, Inc., Chairman at Radius Health, Inc. from 2020 to 2022, Director at Bain Capital Public Equity LP in 2011, Director at Brookside Capital Investors LP, Lead Independent Director at Translate Bio, Inc. from 2016 to 2021, Independent Non-Executive Director at Malin Corp.
Plc from 2015 to 2018, Director at Bain Capital LP, Director at Brookside Capital, Inc. from 2008 to 2013, Independent Director at FS Development Corp.
II, Investment Associate at Ziff Brothers Investments LLC from 2001 to 2003, Financial Analyst at PaineWebber, Inc., and Assistant Vice President at Merrill Lynch Global Private Equity, Inc. from 1998 to 2001.
He was also the Chief Business Officer at Intarcia Therapeutics, Inc. from 2013 to 2017 and Portfolio Manager at FIAM LLC from 2006 to 2008.
Mr. Hughes's education history includes an undergraduate degree from Dartmouth College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
XOMA ROYALTY CORPORATION
0,03% | 18/03/2024 | 3 500 ( 0,03% ) | 82 915 $ | 30/06/2024 |
| 02/10/2023 | 2 000 ( 0,13% ) | 50 720 $ | 30/06/2024 | |
IKENA ONCOLOGY, INC.
-.--% | 07/06/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Postes actifs de Owen Hughes
| Sociétés | Poste | Début |
|---|---|---|
| IKENA ONCOLOGY, INC. | Président | 15/12/2022 |
| XOMA ROYALTY CORPORATION | Directeur Général | 01/01/2023 |
| C4 THERAPEUTICS, INC. | Directeur/Membre du Conseil | 20/11/2023 |
Olivo Laboratories LLC
 Olivo Laboratories LLC Medical/Nursing ServicesHealth Services Olivo Laboratories LLC provides solutions to skin-related medical problems through proprietary biomaterials technologies. Its platform technology consists of a tunable polysiloxane-based material that mimics youthful skin and can be engineered to provide a variety of targeted properties, including elasticity, breathability, invisibility, water resistance, protection. The company was founded by Robert S. Langer Jr. and Richard Rox Anderson and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
Wavebreak Therapeutics Ltd.
 Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom. | Directeur/Membre du Conseil | 29/11/2018 |
Anciens postes connus de Owen Hughes
| Sociétés | Poste | Fin |
|---|---|---|
| RADIUS HEALTH, INC. | Président | 15/08/2022 |
Cullinan Oncology LLC
 Cullinan Oncology LLC Financial ConglomeratesFinance Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA. | Fondateur | 21/10/2021 |
| CULLINAN THERAPEUTICS, INC. | Fondateur | 18/10/2021 |
| TRANSLATE BIO, INC. | Directeur/Membre du Conseil | 14/09/2021 |
| ░░░░░ ░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Owen Hughes
| Dartmouth College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| XOMA ROYALTY CORPORATION | Health Technology |
| MALIN CORPORATION PLC | Health Technology |
| C4 THERAPEUTICS, INC. | Health Technology |
| IKENA ONCOLOGY, INC. | Health Technology |
| CULLINAN THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 17 |
|---|---|
Bain Capital Public Equity LP
 Bain Capital Public Equity LP Investment ManagersFinance Bain Capital Public Equity LP is a SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded in 1996 as Brookside Capital LP. They are wholly-owned by Bain Capital LP, itself a subsidiary of Bain Capital Holdings LP. Bain Capital Public Equity provides investment advisory services to pooled investment vehicles (Public Equity Funds). Investors in the Public Equity Funds includes high net-worth individuals, banks, thrift institutions, pension and profit sharing plans, trusts, estates, charitable organizations, university endowments, corporations, limited partnerships and limited liability companies or other business entities. | Finance |
| Brookside Capital Investors LP | |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
Triathlon Fund Management LLC
 Triathlon Fund Management LLC Investment ManagersFinance Triathlon Fund Management LLC is a hedge fund headquartered in Boston. | Finance |
Translate Bio, Inc.
 Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
Bain Capital LP
 Bain Capital LP Financial ConglomeratesFinance Bain Capital LP engages in provision of investment consulting services. It specializes in private equity, credit, public equity, venture, real estate, double impact, life sciences, and partnership strategies. The company was founded in 1984 and is headquartered in Boston, MA. | Finance |
Brookside Capital, Inc.
 Brookside Capital, Inc. Investment ManagersFinance Brookside Capital, Inc. is an independent wealth management firm headquartered in San Francisco, California. The firm was founded by James Rea in 1989. They provide investment management services to high-net worth individuals and charitable organizations. | Finance |
Ziff Brothers Investments LLC
 Ziff Brothers Investments LLC Investment ManagersFinance Founded in 1992, Ziff Brothers Investments LLC is a hedge fund manager located in New York City. The firm is the primary investment vehicle of the Ziff family, founders of Ziff-Davis Publishing. | Finance |
| PaineWebber, Inc. | Finance |
Merrill Lynch Global Private Equity, Inc.
 Merrill Lynch Global Private Equity, Inc. Investment ManagersFinance Headquartered in New York City, Merrill Lynch Global Partners (MLGP), formerly Merrill Lynch Private Equity Group, is the private equity investment arm of Merrill Lynch & Co., Inc. (NYSE: MER) | Finance |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
FIAM LLC
 FIAM LLC Investment ManagersFinance FIAM LLC (do-business-as Fidelity Institutional Asset Management) is a SEC-registered investment advisor headquartered in Smithfield, Rhode Island. The firm was founded in 2006 and formerly known as Pyramis Global Advisors LLC. They are wholly-owned by FIAM Holdings LLC, which in turn is owned by FMR LLC, aka Fidelity Investments. FIAM provides discretionary investment management services to institutional accounts. The firm also sub-advices funds or accounts for affiliated advisers and unaffiliated advisers. | Finance |
Olivo Laboratories LLC
Olivo Laboratories LLC Medical/Nursing ServicesHealth Services Olivo Laboratories LLC provides solutions to skin-related medical problems through proprietary biomaterials technologies. Its platform technology consists of a tunable polysiloxane-based material that mimics youthful skin and can be engineered to provide a variety of targeted properties, including elasticity, breathability, invisibility, water resistance, protection. The company was founded by Robert S. Langer Jr. and Richard Rox Anderson and is headquartered in Cambridge, MA. | Health Services |
Wavebreak Therapeutics Ltd.
Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA. | Finance |
FS Development Corp. II
 FS Development Corp. II Financial ConglomeratesFinance FS Development Corp. II is a blank check company, which formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more entities. The company was founded by James B. Tananbaum on August 21, 2020 and is headquartered in Larkspur, CA. | Finance |
| Sail Bio, Inc. |
